SOPHiA GENETICS (NASDAQ:SOPH) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

SOPHiA GENETICS (NASDAQ:SOPH) announced its earnings results on Tuesday. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04), Zacks reports. SOPHiA GENETICS had a negative return on equity of 47.40% and a negative net margin of 102.84%. The business had revenue of $15.85 million for the quarter, compared to the consensus estimate of $15.90 million. During the same period in the prior year, the business posted ($0.21) earnings per share. SOPHiA GENETICS updated its FY 2024 guidance to EPS.

SOPHiA GENETICS Price Performance

SOPH remained flat at $3.40 during midday trading on Thursday. 26,325 shares of the company’s stock traded hands, compared to its average volume of 67,867. SOPHiA GENETICS has a 12-month low of $2.70 and a 12-month high of $7.37. The company has a quick ratio of 4.17, a current ratio of 4.40 and a debt-to-equity ratio of 0.11. The stock has a market cap of $222.28 million, a P/E ratio of -3.12 and a beta of 1.03. The stock’s 50 day simple moving average is $3.67 and its 200 day simple moving average is $4.23.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Royal Bank of Canada lowered their target price on shares of SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Morgan Stanley cut shares of SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $10.00 to $5.00 in a research note on Wednesday, August 7th.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.